Arrhythmia, Cancer, Cardiac Disease, Heart Diseases, Metabolic Syndrome
Conditions
Keywords
cancer, heart, cardiovascular, cardio-oncology, onco-cardiology, phamacology, precision medicine
Brief summary
Cardio-oncology is an emerging field. Most of the data available have been issued from either retrospective analysis, industry data or pharmacovigilance data. These data sources include a number of bias. CONFUCIUS is a single tertiary centre prospective registry including all patients who have been referred for cardio-oncology assessemnt. The objectives are to provide a comprehensive vue of cardoi-oncology, enable to detect early signals of cardiotoxicity and enhance ancillary projetcts aiming at specific populations (e.g., type of cancer) and/or drugs.
Interventions
Non applicable
Sponsors
European Georges Pompidou Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* referred to cardio-oncology
Exclusion criteria
* refusal to participate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of cardio-toxicty | 5 years | Number of patients with cardiotoxicity in a cohort of patients referred to a cardio-oncology clinic |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Analysis of cardioprotective strategies | 5 years | Correlation between the use of cardiovascular drugs and the number of patients with cardiotoxicity. |
| Analysis of underlying cardiovacsular profile | 5 years | Correlation between underlying cardioascular profile and the number of patients with cardiotoxicity. |
| Analysis of arrhythmias | 5 years | Correlation between incident arrhythmias and cancer drugs |
| Precision medicine | 5 years | Correlation between biomarkers with use of artificial intelligence and the number of patients with cardiotoxicity. |
| Analysis of cardiotoxicity | 5 years | Correlation of cardio-toxicity overall, and in predefined subgroups; statistical associatoin with outcomes. |
| Cardiovascular outcomes | 10 years | Assess cardiovascular outcomes (cardiovascular death, admission for heart failure, acute coronary syndrome, stroke). |
| Any advserse event | 5 years | Correlation between any adverse event, oncology treatment, and outcomes. |
| Behaviour | 5 years | Correlation of any behaviour treatment (exercice, rehabilitation, nutrition consultation) and the number of patents with cardiotoxocity. |
| Metabolic | 5 years | Correlation between oncology treatments, cardiovascular therapies, behaviour therapies and the number of patients with metabolic disorders (diabetes or dyslipidemia). |
| Oncology | 5 years | Adherence to oncology treatment plan as stated in the multidisciplinary team meeting in patients with cardio-oncology assessment compared to matched patients with no cardio-oncology assessment within our institution; outcomes. |
Countries
France
Contacts
Primary ContactMariana Mirabel, MD, PhD
Outcome results
None listed